Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis by Aapro, M et al.
Effect of treatment with epoetin beta on short-term tumour
progression and survival in anaemic patients with cancer:
a meta-analysis
M Aapro*,1, B Coiffier
2, J Dunst
3,AO ¨ sterborg
4 and HU Burger
5
1Institut Multidisciplinaire d’Oncologie, Clinique de Genolier, 1, route du Muids, CH-1272 Genolier, Switzerland;
2Centre Hospitalier Lyon-Sud, Service
d’Hematologie, Chemin du Grand Revoyet, 69495 Pierre-Benite Cedex, Lyon, France;
3Martin-Luther-University Halle-Wittenberg, Dryanderstrasse 4,
D-06097 Halle, Germany;
4Departments of Oncology and Hematology, Karolinska University Hospital, SE-171 76, Stockholm, Sweden;
5F Hoffmann-La
Roche Ltd, CH-4070 Basel, Switzerland
To assess the early effect of epoetin beta on survival and tumour progression in anaemic patients with cancer, data were pooled from
nine randomised clinical trials comparing epoetin beta with placebo or standard care. Studies were not primarily designed to assess
these end points. Follow-up was for treatment duration plus 4 weeks following therapy completion. All adverse events (AEs) were
retrospectively reviewed blinded, for progression. Thromboembolic events were also assessed. Data analysis involved standard
statistical tests. Overall, 1413 patients were included (epoetin beta, n¼800; control, n¼613; 56% haematological, and 44% solid).
Median initial epoetin beta dose was 30000IU/week. Overall survival during months 0–6 was similar with epoetin beta and control
(0.31 vs 0.32 deaths/patient-year). No increased mortality risk was seen with epoetin beta (relative risk (RR) 0.97, 95% CI: 0.69, 1.36;
P¼0.87). There was a significantly reduced risk of rapidly progressive disease for epoetin beta (RR 0.78, 95% CI: 0.62, 0.99;
P¼0.042). Epoetin beta was associated with a slightly higher frequency of thromboembolic events vs control (5.9% vs 4.2% of
patients) but thromboembolic-related mortality was identical in both groups (1.1%). Epoetin beta provided a slight beneficial effect
on tumour progression and did not impact on early survival or thromboembolic-related mortality.
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Anaemia is commonly seen in patients with cancer, and may result
from malignant disease itself, or from anticancer treatment.
Although the prevalence of anaemia is influenced by both the
type of malignancy and the type of therapy, an adverse effect on
the quality of life (QoL) of patients may result as a consequence of
a variety of symptoms including fatigue, reduced physical capacity,
and impaired cognitive function (Cella, 1998; Caro et al, 2001).
In addition, anaemia is also associated with adverse outcomes in
cancer, with individual studies showing shortened survival in
patients with a variety of malignancies including cancers of the
lung, cervix, head and neck, and prostate cancer, as well as
lymphoma and multiple myeloma (Caro et al, 2001).
This association between impairment of clinical outcomes and
anaemia in patients with cancer has led to the suggestion that
prognosis could be improved if anaemia is corrected. Erythro-
poietic agents have been shown to increase haemoglobin (Hb)
levels and reduce transfusion requirements in patients with cancer
(Littlewood et al, 2001; O ¨sterborg et al, 2002; Vansteenkiste et al,
2002; Boogaerts et al, 2003; Bohlius et al, 2004). Treatment with
epoetin also alleviates fatigue and other symptoms of anaemia and
produces significant improvements in QoL compared with placebo
or standard transfusion therapy (O ¨sterborg et al, 2002; Boogaerts
et al, 2003).
It has been suggested that epoetin therapy may be associated
with delayed tumour progression and improved survival in
patients undergoing cancer therapy. Preclinical data have indi-
cated that administration of epoetin can enhance response to
therapy and delay tumour progression (Mittelman et al, 2001;
Thews et al, 2001; Stuben et al, 2003), whereas early clinical studies
have suggested a potential survival benefit associated with
epoetin in patients receiving radiotherapy and/or chemotherapy
(Antonadou et al, 2001; Glaser et al, 2001; Littlewood et al, 2001).
This hypothesis is supported by results of a meta-analysis of
randomised controlled trials that reported a trend towards
increased survival in patients treated with erythropoietic agents
(Bohlius et al, 2005).
In contrast, an expansion of the above meta-analysis and two
recent studies with survival as the primary end point showed no
such effect and have even suggested that epoetin therapy might
impair survival (Henke et al, 2003; Leyland-Jones et al, 2005;
Bohlius et al, 2006). The robustness of these findings has been
questioned because of methodological limitations, including,
treatment to Hb targets outside of guideline recommendations,
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suse of epoetin beta at twice the recommended dose, protocol
violations, and baseline imbalances favouring the placebo group.
Nevertheless, contrary to much positive evidence, these studies
have fostered the perception that epoetin may have a negative
impact on survival and focussed debate on this important
question. To help address this question, a meta-analysis of
individual patient data from nine controlled clinical studies of
epoetin beta was conducted to further investigate any effect on
disease progression and survival in patients with cancer.
MATERIALS AND METHODS
This meta-analysis of individual patient data was designed to
evaluate differences between epoetin beta and control (placebo or
standard care) with regard to overall survival and malignancy
progression during and up to 28 days after therapy. Differences in
incidence of thromboembolic events were also assessed.
Eligible studies included all randomised, controlled studies of
epoetin beta in patients with cancer undergoing chemotherapy
(seven studies) or surgery (two studies) conducted by the drug
sponsor (F Hoffmann-La Roche or Boehringer Mannheim). A
primary objective was to provide evidence of any effect of epoetin
beta on tumour progression or survival. Given the limitations of
the Henke et al (2003) study design, this radiotherapy study was
excluded from the meta-analysis. A further study that evaluated
the efficacy of epoetin beta once weekly compared with three times
weekly was also excluded because of the lack of a control arm
(Cazzola et al, 2003). Included studies are summarised in Table 1.
None of the included studies were primarily designed to assess
survival and follow-up duration was the standard 4 weeks used to
assess AEs. Deaths reported beyond this period were not included
as follow-up data were not consistently collected after this period
across the studies. Long-term, 12-month follow-up data were
available from one study. These longer-term data were excluded
from the analysis for reasons of consistency and have been
reported elsewhere (O ¨sterborg et al, 2005). Patients were censored
for survival at 4 weeks after the last entry in the administration
record. Although tumour status was not assessed in most of these
trials, details of malignancy progression were reported as AEs,
and these were therefore analysed retrospectively with reviewers
blinded to treatment assignment. Patients without events were
censored as for survival. Adverse event reports were also reviewed
for thromboembolic episodes, with events being classified accord-
ing to a prospectively designed scheme formulated to standardise
the terms used by the different investigating groups across the
studies. AEs, for example, hypertension and headache, were
routinely monitored in individual studies but were not an objective
of the meta-analysis and are therefore not reported. In contrast to
studies of epoetin in patients with renal impairment, pure red cell
aplasia (PRCA) is a rare event in patients in oncology studies.
Therefore, PRCA was not an objective of this meta-analysis and no
patient developed PRCA in this meta-analysis population. The
incidence of these events is typically low and reported elsewhere
(NeoRecormons SmPC, 2006).
In the study by Oberhoff et al (1998), crossover from standard
therapy to epoetin beta was permitted, and patients were censored
at the time of crossover for the purposes of the present analysis. All
patients who received at least one dose of study medication were
included in this analysis.
Statistical analyses
Data on all randomised patients were included in the analyses.
Patients were analysed as treated, with five patients randomised to
control receiving epoetin beta and three patients in the epoetin
beta group receiving no treatment.
Overall and progression-free survival were analysed by Kaplan–
Meier estimates, log-rank testing, and Cox regression analysis
(the last two not stratified by study). Thromboembolic events
were summarised in terms of crude rates independent of
onset. Differences in duration of survival and time to tumour
progression (time between start of epoetin/control therapy, or
baseline visit, and the time of event) were tested using log-rank
Table 1 Main features of randomised clinical trials of epoetin beta in patients with cancer
Study
Design and no. of
patients (epoetin beta/
control) Diagnosis
Epoetin beta dosage and
duration of therapy Control
Cancer
treatment
ten Bokkel Huinink et al
(1998)
o, pg n¼83/37 Ovarian cancer, Hb o13g/dl 150 or 300IU/kg
3 week 6 months
Standard therapy Chemotherapy
O ¨ sterborg et al, (1996) o, pg n¼95/49 MM, NHL, CLL; transfusion-
dependent, Hbo10g/dl
2000–10000IU/day titrated
or 10000IU/day fixed
dosage 24 weeks
Standard therapy Chemotherapy
Rau et al (1998) db, pc, and pg n¼28/26 Resectable rectal cancer;
HbX12.5g/dl (men),
X12g/dl (women)
200IU/kg daily 11 days Placebo Surgery
Kettelhack et al (1998) db, pc n¼52/57 Colorectal cancer suitable for
hemicolectomy,
Hb 48.5–13.5g/dl
20000IU/day 10–15 days Placebo Surgery
Data on file (Study
MF4266)
o, pg n¼10/10 AML 10000IU/day, then weekly or
twice weekly p30 weeks
Standard therapy Chemotherapy
Cazzola et al (1995) o, pg n¼117/29 MM, NHL, CLL; transfusion-
independent, Hbp11g/dl
1000, 2000, 5000, or
10000IU/day 8 weeks
Standard therapy Chemotherapy
Oberhoff et al (1998) pg n¼114/104 Solid organ tumours,
Hb p11g/dl
5000IU/day 12–24 weeks Standard therapy Chemotherapy
Boogaerts et al (2003) o, pg n¼131/128 Malignant disease,
Hbp11g/dl
150IU/kg 3 week adjusted
for Hb response 12 weeks
Standard therapy Chemotherapy
O ¨ sterborg et al (2002) pc, db, and pg n¼170/173 MM, NHL, CLL; transfusion-
dependent and epo-deficient,
Hbp10g/dl
150IU/kg 3 week adjusted
for Hb response 16 weeks
Placebo Chemotherapy
AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; db, double-blind; Hb, haemoglobin; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; o, open design;
pc, placebo-controlled; pg, parallel group. Patients had anaemia unless stated otherwise, and standard therapy consisted of antitumour treatment plus blood transfusion as
required.
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dose or final visit.
A sensitivity analysis for overall and progression-free survival
that excluded studies outside of the normal clinical usage of
epoetin beta (two studies in patients undergoing pre-operative
cancer surgery and one in patients with acute myeloid leukaemia
(AML)) was also performed.
RESULTS
A total of 1413 patients were included in this analysis (epoetin
beta, n¼800; control, n¼613). Of these, 56% had haematological
malignancies and 44% had solid tumours (Table 2). Five patients
originally classified as ‘other’ were later diagnosed with Hodgkin’s
lymphoma. Most patients with solid tumours had primary
malignancies of the breast, colon/rectum, or ovary. Among
patients with haematological tumours, 56% had non-Hodgkin’s
lymphoma, and 42% had multiple myeloma. There were no
significant differences in tumour type between treatment groups,
with the exception of a slightly higher proportion of patients with
ovarian cancer in the epoetin beta group because of the three-arm
design used in the study by ten Bokkel Huinink et al (1998). Data
on tumour stage at baseline was not available for all patients as
tumour progression was not a predefined objective in any of the
studies. However, information on tumour stage was available for
approximately 75% of patients with solid tumours and 80% of
patients with haematological malignancies. There was no obvious
difference in tumour staging between treatment and control
groups.
Median initial weekly epoetin beta dose was 30000IU (range
1143–90000IU). Mean baseline Hb level was 9.9gdl
 1 in both
treatment groups whereas mean maximum Hb during treatment
was 12.6gdl
 1 with epoetin beta and 11.6gdl
 1 with control. Mean
baseline-adjusted Hb area under the curve was 1.01gdl
 1 with
epoetin beta compared with 0.16gdl
 1 with control, indicating an
overall Hb difference of approximately 1.0gdl
 1 during treatment.
Duration of follow-up was generally similar in both groups,
being limited to treatment duration plus a standard 4-week period.
However, more patients were available for follow-up from 4–6
months in the epoetin beta group compared with control, which
may have introduced a slight bias favouring control in subsequent
analyses.
Survival
There was no significant difference between epoetin beta and
control in terms of overall survival during the observation period.
The death rate was similar with epoetin beta compared with
control (0.31 vs 0.32 deaths/patient-year). Kaplan–Meier analysis
showed no relevant difference between epoetin beta and control,
with respective event rates of 10.0 and 9.5% and an overall hazard
ratio (HR) of 0.97 (95% CI 0.69, 1.36; log-rank, P¼0.87) (Figures
1A and 2A, respectively).
In patients with solid tumours, the death rate was slightly lower
with epoetin beta compared with control (0.21 vs 0.24 deaths/
patient-year), whereas in patients with haematological malignan-
cies the death rate was 0.39 with epoetin beta compared with 0.37
with control. Kaplan–Meier and Cox regression analysis of results
by tumour type showed no difference between groups in risk of
death for either haematological or solid tumours (Table 3).
Multivariate Cox regression analysis of survival adjusted for the
prognostic factors age, gender, tumour type (solid vs haematolo-
gical), and baseline Hb level showed no change in the treatment
effect estimates for epoetin beta (adjusted HRs ranging from 0.97
(95% CI 0.69, 1.36) to 1.00 (95% CI 0.71, 1.41). The result of the
Cox regression analysis stratified by study was consistent with the
primary unstratified analysis (HR 1.04, P¼0.84).
Table 2 Baseline characteristics of pooled study populations
Parameter Control (n¼613) Epoetin beta (n¼800)
Gender (% male) 40 40
Race
N 481 625
Caucasian 469 (98%) 612 (98%)
Other 12 (2%) 13 (2%)
Mean age in years (range) 60.8 (19–91) 61.1 (20–87)
Mean weight in kg (range) 67.3 (40.0–112.0) 66.8 (35.0–118.0)
N 482 663
Mean height in cm (range) 165.7 (140–198) 165.4 (126–190)
N 603 800
Tumour type
Haematological
a 331 (54%) 465 (58%)
Solid 282 (46%) 335 (42%)
Haemoglobin (g/dl)
N 613 798
Mean (range) 9.94 (5.7–16.7) 9.86 (4.2–17.1)
Median 9.80 9.70
Data were collected from all 1413 patients unless stated otherwise.
aFive patients
were originally classified under ‘other tumour type’ but were later diagnosed with
Hodgkin’s lymphoma.
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Figure 1 Kaplan–Meier curves of (A) overall survival and (B) time to
progression.
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Figure 2 Summary of HRs of (A) overall survival and (B) time to progression.
Table 3 Kaplan–Meier and Cox regression analysis of survival and time to progression data
Control (n¼613) Epoetin beta (n¼800)
Patient group
Total
events
Mean patient-years
of follow-up
Events per
patient-year
Total
events
Mean patient-years
of follow-up
Events per
patient-year
Hazard ratio
(95% CI)
Overall survival
Total 58 0.30 0.32 80 0.32 0.31 0.97 (0.69–1.36)
Tumour type
Solid 17 0.25 0.24 22 0.32 0.21 0.94 (0.50–1.78)
Haematological 41 0.34 0.37 58 0.32 0.39 1.04 (0.69–1.55)
Time to progression
Total 133 0.27 0.81 145 0.29 0.62 0.78 (0.62–0.99)
Tumour type
Solid 50 0.23 0.78 50 0.30 0.50 0.71 (0.48–1.06)
Haematological 82 0.31 0.81 93 0.29 0.69 0.84 (0.62–1.13)
‘Events’ refers to number of deaths for ‘overall survival’, and to number of malignant disease progressions for ‘time to progression’.
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Although there were no apparent clinically significant differences
between treatment and control groups in the number of tumour
progressions in individual trials, rate of tumour progression was
lower with epoetin beta than control in the meta-analysis (0.62 vs
0.81events/patient-year) (Table 3). Kaplan–Meier analysis also
showed a reduced risk of progression among patients treated with
epoetin beta (HR 0.78, 95% CI 0.62, 0.99; log-rank test, P¼0.042)
(Figures 1B and 2B, respectively).
Subgroup analyses of patients with solid tumours and haema-
tological malignancies were consistent with the overall population
(Table 3). Relative risk (RR) for tumour progression with epoetin
beta compared with control was 0.71 (95% CI 0.48, 1.06) in patients
with solid tumours and 0.84 (95% CI 0.62, 1.13) in patients with
haematological malignancies.
As with overall survival, multivariate regression analysis to
adjust for prognostic factors (age, gender, tumour type, and
baseline Hb level) did not alter the treatment effect estimates
(adjusted HR from 0.78 (95% CI 0.62, 0.99) to 0.81 (95% CI 0.64,
1.03)). The result of the Cox regression analysis stratified by study
was consistent with the primary finding (HR 0.85, P¼0.19).
Exclusion of studies outside normal approved clinical
usage
A sensitivity analysis was performed in a subset of patients
(epoetin beta, n¼710; control, n¼520) that excluded the three
studies outside of the normal clinical usage of epoetin beta (two
studies in patients with pre-operative cancer surgery (O ¨sterborg
et al, 1996; Rau et al, 1998) and one in patients with AML (data
on file)). A further study in anaemic patients with head and
neck cancer receiving radiotherapy (Henke et al, 2003), was also
excluded as more than 80% of patients were treated to a Hb level
414gdl
 1. Overall results for both survival (HR 0.93, 95% CI 0.66,
1.33; P¼0.70) and time to progression (HR 0.79, 95% CI 0.62, 1.01;
P¼0.058) were consistent with those for the whole population.
Thromboembolic events
There was a small excess of thromboembolic events in the epoetin
beta group (5.9 vs 4.2% of patients with at least one event), which
was largely accounted for by reports of thrombosis, deep vein
thrombosis, and pulmonary embolism. The proportion of patients
who died as a result of thromboembolism was the same (1.1%)
in each group. Similar results were obtained when results were
analysed by tumour type.
There was a slightly higher incidence of thromboembolism in
terms of events per patient-year with epoetin beta over control in
most of the studies when considered separately, as well as in this
meta-analysis. Incidences were 0.19 events per patient-year in the
epoetin beta group and 0.14 in the control group. The RR was
slightly lower when analysing events per patient-year than when
using crude rates (1.30 for events per patient-year and 1.40 for
crude rates). Therefore, differences in the observation time may
have contributed to the differences in crude rates.
There were no apparent major differences between studies or
between patients with solid tumours compared with haematological
malignancies with regard to frequency of thromboembolic events.
DISCUSSION
The results of the present meta-analysis show no evidence that
treatment with epoetin beta impairs survival or promotes tumour
progression in patients with cancer, at least during the period of
observation.
These data are concordant with evidence from some preclinical
studies that suggest that epoetin may improve cyto- and radio-
sensitivity and impair progression of various tumours. Correction
of anaemia by epoetin has been reported to improve cyclophos-
phamide cytotoxicity in a rat model (Thews et al, 2001) and to
restore radiosensitivity of experimental human tumours in nude
mice (Stuben et al, 2003). Also, one study using a murine myeloma
model reported that epoetin induced tumour regression and
antitumour immune responses (Mittelman et al, 2001). However,
other preclinical data, primarily obtained from cell lines, have
suggested that epoetin may diminish the effects of cytostatic agents
or promote tumour cell growth in vitro (Acs et al, 2003; Farrell and
Lee, 2004).
Some clinical studies have suggested reduced tumour progres-
sion and increased survival in anaemic patients with cancer treated
with epoetin. In a non-randomised study of 191 patients under-
going neoadjuvant chemoradiotherapy and resection for squamous
cell carcinoma of the oral cavity or oropharynx, treatment with
epoetin was associated with significantly better local control and
survival compared with an untreated historical control group
(Glaser et al, 2001). Similarly, in a preliminary report, treatment
with epoetin improved tumour control and survival in a
randomised controlled trial of 385 patients with various pelvic
malignancies receiving radiotherapy (Antonadou et al, 2001). A
nonsignificant trend towards a survival benefit with epoetin has
also been suggested by the results of a randomised, double-blind,
placebo-controlled trial of 375 patients with solid or non-myeloid
haematological malignancies receiving non-platinum-based chemo-
therapy (Littlewood et al, 2001). In addition, a recent meta-analysis
by Bohlius et al (2005) of randomised controlled trials in patients
with cancer also reported a trend towards improved survival with
epoetin (HR 0.84, 95% CI 0.69–1.02, n¼2805). Although
subsequent expansion of this analysis showed a shift towards
increased mortality risk and increased risk from thromboembolic
events, this was suggested by the authors as being possibly
due to methodological limitations such as baseline imbalances
(Bohlius et al, 2006). One prospective study investigating the
role of dose-dense chemotherapy in patients with early
breast cancer has demonstrated that epoetin alfa had no adverse
influence on survival (Mo ¨bus et al, 2004). A similarly neutral
effect on survival was also reported in a meta-analysis of four
randomised, double-blind, placebo-controlled studies of darbepoe-
tin alfa in patients with a variety of tumour types (Hedenus et al,
2005).
In contrast, two prospective, randomised studies in which
survival was a primary end point have been less positive, and have
even suggested that therapy with epoetin could have a detrimental
effect on survival (Henke et al, 2003; Leyland-Jones et al, 2005).
The study by Henke et al (2003) was a double-blind study in 351
patients with carcinoma of the oral cavity, oropharynx, hypo-
pharynx, or larynx treated with curative radiotherapy. In this
study, epoetin beta was reported to increase Hb levels relative to
placebo. However, there was also a reduction in both locoregional
progression-free survival (adjusted RR 1.62; 95% CI 1.22, 2.14;
Po0.001) and overall survival (adjusted RR of death 1.39; 95% CI
1.05, 1.84; P¼0.02) relative to placebo. The study by Leyland-
Jones et al (2005), in which patients receiving first-line
chemotherapy for metastatic breast cancer were treated with
epoetin alfa for the prevention of anaemia, was terminated early
because of a significant (P¼0.01) difference in 12-month survival
between patients in the epoetin alfa (70%) and placebo (76%)
groups (Leyland-Jones et al, 2005).
However, these two studies need to be interpreted with caution,
as baseline imbalances in prognostic factors favoured placebo
in both. Other limitations of these two studies have also been
highlighted (Dunst, 2004; Leyland-Jones and Mahmud, 2004;
Vaupel and Mayer, 2004). Moreover, it should be noted that both
trials were investigational in nature and both used epoetin outside
of its currently approved indications (in predominantly mild or
non-anaemic patients, many of whom attained higher than
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tions, along with reports that the apparent negative effect of
epoetin beta observed in the Henke et al (2003) study simply
reflects over-treatment (Vaupel and Mayer 2004), led to exclusion
of the Henke et al study (2003) from this meta-analysis.
This meta-analysis takes into account epoetin beta studies not
included in the previous meta-analysis of epoetin randomised
controlled trials (Bohlius et al, 2005). The findings, together with
evidence from other studies (Food and Drug Administration, 2004)
suggest there is no indication of an increase in early disease
progression and that epoetin does not impair survival in patients
with anaemia when used as currently approved. Furthermore, the
results of the present study indicate a trend towards a reduced rate
of tumour progression with epoetin beta treatment.
Long-term follow-up data from one of the studies included in
this analysis provide further evidence that epoetin beta has a
neutral effect on survival. In this randomised, double-blind trial of
severely anaemic patients with lymphoproliferative malignancy,
median survival was 17 months with epoetin beta and 18 months
with placebo and Kaplan–Meier curves for survival were similar
for both treatment groups (O ¨sterborg et al, 2005).
Cancer and its treatment are known predictors of risk for
thromboembolism, with absolute risk depending on tumour type,
stage, and extent of cancer and treatment, and on other factors
such as age, surgery, immobilisation, and comorbid features (Lee
and Levine, 2003). Treatment with epoetin has been associated
with occasional reports of thromboembolic events and this is
reflected in the product label. The present meta-analysis, as well as
that by Bohlius et al (2005), showed a marginal increase in
incidence of thromboembolism in patients receiving epoetin.
Importantly, in our analysis, epoetin was not associated with any
increase in the proportion of patients with thromboembolic events
leading to death.
This meta-analysis of nine controlled trials, which represents all
randomised, controlled trials of epoetin beta within its current
indication, shows no evidence of a negative effect on survival
or thromboembolic-related mortality of epoetin beta in patients
with cancer. Moreover, these data show a small but statistically
significant benefit in slowing tumour progression compared with
placebo or standard transfusion therapy. Within its licensed
indication, our results indicate that epoetin beta is a safe treatment
of anaemia for patients with cancer.
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